Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

uniQure Announces Submission of Biologics License Application for Ifezuntirgene ...

2 September 2026 · By · Wire by Fusion42

Published

2 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at uniqure.gcs-web.com →

◆ Verified

Fusion42 · 2 September 2026 · Fusion42 review

uniQure has submitted a Biologics License Application to the US FDA and a Marketing Authorisation Application to the UK MHRA for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington's disease, supported by three-year clinical data showing slowed disease progression.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

The FDA's priority review request signals a fast path to market for uniQure's Huntington's gene therapy. You should assess readiness for rapid regulatory feedback and prepare for accelerated market entry in the US and UK.

◆ Coverage

1 source · 2 Sep 2026

◆ Related on Wire

◆ Topics

Biotechgene-therapyhuntingtons-diseaseregulatory-approvalbiologics-license-applicationFDAMHRA